A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Clinical trial NCT05319730 · RECRUITING
Trial details
- NCT number
- NCT05319730
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-16
- Primary completion
- 2027-06-11
- Enrollment
- 230
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.